Overview

A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer

Status:
Withdrawn

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate changes in the expression of targeted biomarkers in invasive breast cancer tissue before and after SNDX-275 administration.

Phase:

Phase 1

Details

Lead Sponsor:

Syndax Pharmaceuticals

Treatments:

Entinostat